Medications and cataract: The blue mountains eye study

Ophthalmology

Volumn 105, Issue 9, 1998, Pages 1751-1758

  Cumming, Robert G ^a   Mitchell, Paul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANTIMALARIAL AGENT; CHLOROQUINE; CORTICOSTEROID; DIURETIC AGENT; FUROSEMIDE; MEPACRINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOTHIAZINE; SIMVASTATIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATARACT; CORTICOSTEROID THERAPY; DRUG EFFECT; EYE PROTECTION; FEMALE; HUMAN; LENS IMPLANT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POPULATION RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0031732685     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)99049-2     Document Type: Article

References (45)

1. Hodge WG, Whitcher JP, Satariano W. Risk factors for age-related cataracts. Epidemiol Rev 1995;17:336-46.
2. Fraunfelder FT, Hanna C, Dreis MW, Cosgrove KW Jr. Cataracts associated with allopurinol therapy. Am J Ophthalmol 1982;94:137-40.
3. Lerman S, Megaw J, Fraunfelder FT. Further studies on allopurinol therapy and human cataractogenesis. Am J Ophthalmol 1984;97:205-9.
4. Liu CS, Brown NA, Leonard TJ, et al. The prevalence and morphology of cataract in patients on allopurinol treatment. Eye 1988;2:600-6.
5. Leske MC, Chylack LT Jr, Wu SY. The Lens Opacities Case-Control Study. Risk factors for cataract. Arch Ophthalmol 1991;109:244-51.
6. Jick H, Brandt DE. Allopurinol and cataracts. Am J Ophthalmol 1984;98:355-8.
7. Clair WK, Chylack LT Jr, Cook EF, Goldman L. Allopurinol use and risk of cataract formation. Br J Ophthalmol 1989;73: 173-6.
8. Siddall JR. The ocular toxic findings with prolonged and high dosage chlorpromazine intake. Arch Ophthalmol 1965;74: 460-4.
9. Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with chlorpromazine therapy. Can Med Assoc J 1964;90:663-5.
10. Isaac NE, Walker AM, Jick H, Gorman M. Exposure to phenothiazine drugs and risk of cataract. Arch Ophthalmol 1991;109:256-60.
11. Bernstein HN. Chloroquine ocular toxicity. Surv Ophthalmol 1967;12:415-47.
12. Harding JJ, van Heyningen R. Drugs, including alcohol, that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide. Br J Ophthalmol 1988;72:809-14.
13. Klein BEK, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology 1985;92:1191-6.
14. Clayton RM, Cuthbert J, Duffy J, et al. Some risk factors associated with cataract in SE Scotland: a pilot study. Trans Ophthalmol Soc UK 1982;102:331-6.
15. Szmyd L Jr, Schwartz B. Association of systemic hypertension and diabetes mellitus with cataract extraction. A case-control study. Ophthalmology 1989;96:1248-52.
16. Flach AJ, Dolan BJ, Sudduth B, Weddell J. Amiodarone-induced lens opacities. Arch Ophthalmol 1983;101:1554-6.
17. Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol 1996;40:320-37.
18. Adamsons I, Munoz B, Enger C, Taylor HR. Prevalence of lens opacities in surgical and general populations. Arch Ophthalmol 1991;109:993-7.
19. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. New Engl J Med 1997; 337:8-14.
20. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-60.
21. Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in Australia. The Blue Mountains eye study. Ophthalmology 1997;104:581-8.
22. Klein BEK, Klein R, Linton KLP, et al. Assessment of cataracts from photographs in the Beaver Dam Eye Study. Ophthalmology 1990;97:1428-33.
23. Panchapakesan J, Cumming RG, Mitchell P. Reproducibility of the Wisconsin cataract grading system in the Blue Mountains Eye Study. Ophthalmic Epidemiol 1997;4:119-26.
24. Armstrong BG, Sloan M. Ordinal regression models for epidemiologic data. Am J Epidemiol 1989;129:191-204.
25. Cotlier E, Sharma YR. Aspirin and senile cataracts in rheumatoid arthritis [letter]. Lancet 1981;1:338-9.
26. Cotlier E. Senile cataracts: evidence for acceleration by diabetes and deceleration by salicylate. Can J Ophthalmol 1981; 16:113-8.
27. van Heyningen R, Harding JJ. Do aspirin-like analgesics protect against cataract? A case-control study. Lancet 1986;1:1111-3.
28. Harding JJ, Egerton M, Harding RS. Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol (Copenh) 1989;67:518-24.
29. Mohan M, Sperduto RD, Angra SK, et al. India-US case-control study of age-related cataracts. India-US Case-Control Study Group (published erratum appears in Arch Ophthalmol 1989;107:1288). Arch Ophthalmol 1989;107:670-6.
30. Chen TT, Hockwin O, Eckerskorn U, et al. Cataract and health status. A case-control study revisited. Dev Ophthalmol 1989; 17:6-12.
31. West SK, Munoz BE, Newland HS, et al. Lack of evidence for aspirin use and prevention of cataracts. Arch Ophthalmol 1987;105:1229-31.
32. Chew EY, Williams GA, Burton TC, et al. Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 16. Arch Ophthalmol 1992;110:339-42.
33. Seddon JM, Christen WG, Manson JA, et al. Low-dose aspirin and risks of cataract in a randomized trial of US physicians. Arch Ophthalmol 1991;109:252-5.
34. Does aspirin affect the rate of cataract formation? Cross-sectional results during a randomised double-blind placebo controlled trial to prevent serious vascular events. UK-TIA Study Group. Br J Ophthalmol 1992;76:259-61.
35. Seigel D, Sperduto RD, Ferris FL III. Aspirin and cataracts. Ophthalmology 1982;89:47A-9A.
36. Klein BEK, Klein R, Moss SE. Is aspirin use associated with lower rates of cataracts in diabetic individuals? Diabetes Care 1987;10:495-9.
37. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-50.
38. Hankinson SE, Seddon JM, Colditz GA, et al. A prospective study of aspirin use and cataract extraction in women. Arch Ophthalmol 1993;111:503-8.
39. Kewitz H, Nitz M, Gaus V. Aspirin and cataract [letter]. Lancet 1986;2:689.
40. Klein BEK, Klein R, Jensen SC, Linton KL. Hypertension and lens opacities from the Beaver Dam Eye Study. Am J Ophthalmol 1995;119:640-6.
41. Ye JJ, Zadunaisky JA. A Na+/H+ exchanger and its relation to oxidative effects in plasma membrane vesicles from lens fibers. Exp Eye Res 1992;55:251-60.
42. Benos DJ. Amiloride: a molecular probe of sodium transport in tissues and cells. Am J Physiol 1982;242:C131-45.
43. Harris ML, Bron AJ, Brown NAP, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995;79:996-1002.
44. Collman GW, Shore DL, Shy CM, et al. Sunlight and other risk factors for cataracts: an epidemiologic study. Am J Public Health 1988;78:1459-62.
45. Epidemiology of cataract [editorial]. Lancet 1982;1:1392-3.